With COVID-19 vaccine stocks Pfizer and Moderna receiving so much attention, the author of today’s article notes that “This leaves a lot of biotech stocks lacking the attention they deserve. While this is bad news for current holders of these stocks, it is an opportunity for new ones.” With this in mind, he proceeds to highlight three “under-loved” biotech stocks with more upside potential than downside risk to consider for profits in 2021. For these three stocks, CLICK HERE.
In making the case for why the biotech featured in today’s article, which is focused on the development of novel antibody-drug conjugate therapeutics for the treatment of cancer, is an attractive investment, the analyst cited points to three primary factors: “the favorable outlook for [its lead candidate], the long-term potential of the biotech’s pipeline and the continuing validation, by partners, of its proprietary technology.” For more on the biotech in question and each of these factors making it an appealing pick, CLICK HERE.
“Biopharma stocks are risky bets that could fetch disproportionate gains or wipe away one’s entire investment thanks to their vulnerability to catalytic events,” acknowledges the author of today’s article before proceeding to identify nine biotech stocks with key catalysts in the final months of 2020. For these nine stocks and their respective fourth-quarter catalysts and price targets, CLICK HERE.
With their shares having surged by more than 484%, 500% and 275%, respectively, the three stocks highlighted in today’s article are three of the best-performing pharmaceutical stocks over the past year – and despite them having already experienced monster moves higher, it may not be too late to get in on these stocks’ gains. For more on these three pharmaceutical stocks, how much higher each can possibly go, and which may be the safest (and the riskiest) bet, CLICK HERE.
Biotech stocks have weathered the coronavirus selloff pretty well on the whole – and today’s article notes that “Several biotechs have delivered solid gains in the midst of the overall stock market plunge.” For three top biotech stock picks that have been beating the market and that still have lots of room to run from here – including one “oddball” biotech pick that has no approved products on the market and no profits but does have a potential vaccine for COVID-19 and a potential blockbuster flu vaccine – CLICK HERE.
How can investors – especially retired investors – beat the market without fail? The author of today’s article outlines “a simple step-by-step common sense-based strategy” to do just that, with the following caution: “What I will be presenting may not be what you are expecting, particularly if you have a narrow notion of what beating the market means. In other words, one of my primary objectives will be to expand your mind and attitudes regarding what investment performance is truly all about.” For more, CLICK HERE.
“It’s easier than you think to identify Warren Buffett’s top retirement stock. Don’t overthink it. It’s his own company: Berkshire Hathaway,” declares the author of today’s article, who identifies the “secret” that allows Berkshire to deliver such impressive returns – and which makes it “the single best retirement stock out there today.” For this – and more reasons why Berkshire is a perfect stock for retirees – CLICK HERE.
Socially Responsible Investing (SRI) and Environmental, Social and Corporate Governance (ESG) have been gaining popularity as investment approaches, but are ESG/SRI funds good for retirees and soon-to-be-retirees? The author of today’s article believes that “The ensuing debate over SRI and ESG investing is potentially an existential one for retirees and soon-to-be retirees”, given the question as to whether these approaches lead to diminished – or superior – returns. What does the research have to say about the suitability of ESG/SRI funds for retirees? CLICK HERE.
With the market butting up against all-time highs, those who are about to retire may be feeling particularly concerned, given sequence of returns risk and the potentially catastrophic effect of poor returns early on in retirement. For those nervous near-retirees, today’s article may provide some comfort as it outlines what a research team found when it comes to retiring at an all-time high in the market versus retiring at a random time in the market. For more, CLICK HERE.
While he acknowledges that they are “kind of boring”, when it comes to this retirement investment, the author of today’s article argues that “boring is brilliant.” The investment in question? Target-date funds. He proceeds to outline a number of reasons why investors should embrace these “boring” investment vehicles – and a simple strategy to overcome one of their few shortcomings and “wind up with anywhere from 10% to 50% more money in retirement.” For more, CLICK HERE.